Table 1 Demographic, anatomopathological and biological data of the cohort. Twenty-three colorectal cancer tumor tissues were included and 22 circulating tumor DNA. For 11 of the tumor tissues, non-tumor tissues close to the tumor were analyzed. The anatomopathological and biological results come from analyses carried out as part of patient management
Tumor/non-tumor tissues pairs (n = 11) | Tumor tissues (n = 12) | ctDNA (n = 22) | |
|---|---|---|---|
Sex, n (%) | |||
Men | 5 (45%) | 6 (50%) | 16 (73%) |
Women | 6 (55%) | 6 (50%) | 6 (27%) |
Age in years, mean (min-max) | |||
60 (44–79) | 75 (55–84) | 63 (36–82) | |
Location of the tumor, n (%) | |||
Duodenum | / | 1 (8%) | / |
Cecum | 2 (18%) | 2 (17%) | 2 (9%) |
Right colon | 2 (18%) | 6 (50%) | 3 (13%) |
Transverse colon | / | 2 (17%) | 1 (5%) |
Left colon | 5 (46%) | / | 11 (50%) |
Rectosigmoid junction | 1 (9%) | 1 (8%) | 1 (5%) |
Rectum | 1 (9%) | / | 4 (18%) |
Conservation, n (%) | |||
FFPE | 8 (72%) | 12 (100%) | / |
Freezing | 3 (28%) | / | / |
Histology, n (%) | |||
ADC | 11 (100%) | 12 (100%) | 19 (86%) |
Tubular adenoma | / | / | 1 (5%) |
NA | / | / | 2 (9%) |
Stage, n (%) | |||
I | 1 (9%) | 2 (17%) | 2 (9%) |
II | 4 (37%) | 5 (42%) | / |
III | 3 (27%) | 2 (17%) | / |
IV | 3 (27%) | 2 (17%) | 20 (91%) |
ND | / | 1 (8%) | / |
Microsatellite stability, n (%) | |||
MSS | 7 (64%) | 2 (17%) | 16 (72%) |
MSI | 3 (27%) | 10 (83%) | 1 (5%) |
NA | 1 (9%) | / | 5 (23%) |
Mutational status, n (%) | |||
KRAS mutation | 3 (27%) | 3 (25%) | 7 (32%) |
NRAS mutation | / | / | 2 (9%) |
BRAF mutation | 3 (27%) | 4 (33%) | 1 (5%) |
Other mutations | / | / | 1 (5%) |
No mutation | 1 (9%) | 5 (42%) | 11 (50%) |
NA | 4 (36%) | / | / |
MLH1 methylation, n (%) | |||
Presence (≥ 5%) | 3 (27%) | 9 (75%) | / |
Absence (< 5%) | / | 3 (25%) | / |
NA | 8 (73%) | / | 22 (100%) |